Cost-Effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients

Summary:Adherence to antiretroviral medications has been shown to be an important factor in predicting viral suppression and clinical outcomes. The objective of this analysis was to assess the cost-effectiveness of a nursing intervention on antiretroviral adherence using data from a randomized controlled clinical trial as input to a computer-based simulation model of HIV disease. For a cohort of HIV-infected patients similar to those in the clinical trial (mean initial CD4 count of 319 cells/mm3), implementing the nursing intervention in addition to standard care yielded a 63% increase in virologic suppression at 48 weeks. This produced increases in expected survival (from 94.5 to 100.9 quality-adjusted life months) and estimated discounted direct lifetime medical costs ($253,800 to $261,300). The incremental cost-effectiveness ratio for the intervention was $14,100 per quality-adjusted life year gained compared with standard care. Adherence interventions with modest effectiveness are likely to provide long-term survival benefit to patients and to be cost-effective compared with other uses of HIV care funds.

[1]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[2]  Milton C Weinstein,et al.  Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. , 2003, The American journal of medicine.

[3]  B. Laurence,et al.  Efficacy of an Educational and Counseling Intervention on Adherence to Highly Active Antiretroviral Therapy: French Prospective Controlled Study , 2003 .

[4]  Richard D Moore,et al.  Costs of HIV medical care in the era of highly active antiretroviral therapy. , 1999, AIDS.

[5]  M. Otto,et al.  Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. , 2001, Behaviour research and therapy.

[6]  J. Robins,et al.  Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. , 2003, American journal of epidemiology.

[7]  M. Prins,et al.  Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review , 2004, Journal of hypertension.

[8]  T. Tripp,et al.  A Randomized Controlled Trial to Enhance Antiretroviral Therapy Adherence in Patients with a History of Alcohol Problems , 2005, Antiviral therapy.

[9]  J. Tolson,et al.  Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients. , 2003, Journal of acquired immune deficiency syndromes.

[10]  H. Günthard,et al.  Effect of Individual Cognitive Behaviour Intervention on Adherence to Antiretroviral Therapy: Prospective Randomized Trial , 2004, Antiviral therapy.

[11]  S. Hammer,et al.  Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. , 2004, JAMA.

[12]  R. D. Bruce,et al.  Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Douglas K Owens,et al.  Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. , 2005, The New England journal of medicine.

[14]  M. Weinstein,et al.  Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. , 2005, The American journal of medicine.

[15]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[16]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[17]  John Urquhart,et al.  Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. , 2003, The Journal of rheumatology.

[18]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[19]  T. Flanigan,et al.  Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R. Walensky,et al.  Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Weinstein,et al.  Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. , 2002, Archives of internal medicine.

[22]  Elena Losina,et al.  Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness , 2001, Annals of Internal Medicine.

[23]  Milton C Weinstein,et al.  Comparison of Health State Utilities Using Community and Patient Preference Weights Derived from a Survey of Patients with HIV/AIDS , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[24]  R. Hays,et al.  A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors , 2001, Annals of Internal Medicine.

[25]  Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. , 2003, HIV clinical trials.

[26]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[27]  M. Weinstein,et al.  Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  V. Johnson,et al.  Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370 , 2001, Antiviral therapy.

[29]  Peter A Ubel,et al.  What is the price of life and why doesn't it increase at the rate of inflation? , 2003, Archives of internal medicine.

[30]  B. Conway,et al.  Directly observed therapy for the management of HIV-infected patients in a methadone program. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  K. Holmes,et al.  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  C. Flexner.  Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[33]  J. Montaner,et al.  Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials , 2005, Journal of acquired immune deficiency syndromes.

[34]  Judith Chwalow,et al.  Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. , 2003, Journal of acquired immune deficiency syndromes.

[35]  K. Tashima,et al.  Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.

[36]  R. Gross,et al.  A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. , 2004, Journal of clinical epidemiology.

[37]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[38]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[39]  Milton C Weinstein,et al.  Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.

[40]  S. Morton,et al.  Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. , 2000, Health services research.

[41]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[42]  B Clotet,et al.  Prospective Randomized Two‐Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long‐Term Adherence to Highly Active Antiretroviral Therapy , 2000, Journal of acquired immune deficiency syndromes.

[43]  D. McCaffrey,et al.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.

[44]  M. Weinstein,et al.  Cost-Effectiveness of Enfuvirtide in Treatment-Experienced Patients With Advanced HIV Disease , 2005, Journal of acquired immune deficiency syndromes.

[45]  Injury rates by industry 1970, BLS Report 406, Department of Labor, Bureau of Labor Statistics. , 1972, IMS, Industrial medicine and surgery.

[46]  K. Tashima,et al.  Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  L. Eldred,et al.  The cost of HIV medication adherence support interventions: Results of a cross-site evaluation , 2005, AIDS care.

[48]  R. W. Burgess,et al.  BUREAU OF THE CENSUS , 1992 .

[49]  D. Nicolau,et al.  Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  Chester H. Ponikowski,et al.  OF THE NATIONAL COMPENSATION SURVEY , 2002 .

[51]  W. Bilker,et al.  Effect of adherence to newly initiated antiretroviral therapy on plasma viral load , 2001, AIDS.

[52]  M C Weinstein,et al.  The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.

[53]  Cost effectiveness of combination HIV therapy: 3 years later. , 2000, PharmacoEconomics.